Maze Therapeutics Inc
MAZE45.030USD
+1.080+2.46%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
2.16BCap. mercado
PérdidaP/E TTM
Más Datos de Maze Therapeutics Inc Compañía
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Información de Maze Therapeutics Inc
Símbolo de cotizaciónMAZE
Nombre de la empresaMaze Therapeutics Inc
Fecha de salida a bolsaJan 31, 2025
Director ejecutivoColoma (Jason V)
Número de empleados125
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección171 Oyster Point Boulevard, Suite 300
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16508505070
Sitio Webhttps://www.mazetx.com/
Símbolo de cotizaciónMAZE
Fecha de salida a bolsaJan 31, 2025
Director ejecutivoColoma (Jason V)
Ejecutivos de Maze Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
+3.00%
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ms. Courtney J. Phillips
Ms. Courtney J. Phillips
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
+3.00%
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Desglose de ingresos
FY2025Q3
FY2025Q2
FY2024
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: lun., 17 de nov
Actualizado: lun., 17 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Third Rock Ventures, LLC
11.27%
Frazier Life Sciences Management, L.P.
9.49%
ARCH Venture Partners
8.56%
Deep Track Capital LP
8.21%
Alphabet, Inc.
5.01%
Otro
57.45%
Accionistas
Accionistas
Proporción
Third Rock Ventures, LLC
11.27%
Frazier Life Sciences Management, L.P.
9.49%
ARCH Venture Partners
8.56%
Deep Track Capital LP
8.21%
Alphabet, Inc.
5.01%
Otro
57.45%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
35.70%
Hedge Fund
16.44%
Investment Advisor/Hedge Fund
13.22%
Private Equity
10.76%
Investment Advisor
9.98%
Individual Investor
1.88%
Family Office
1.00%
Research Firm
0.45%
Endowment Fund
0.19%
Otro
10.36%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
154
41.80M
86.88%
+1.94M
2025Q3
111
39.53M
83.57%
-194.63K
2025Q2
100
42.58M
97.22%
+13.88M
2025Q1
93
44.69M
102.04%
+15.27M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Third Rock Ventures, LLC
5.42M
11.27%
-1.60M
-22.78%
Nov 04, 2025
Frazier Life Sciences Management, L.P.
4.57M
9.49%
-1.00
-0.00%
Sep 30, 2025
ARCH Venture Partners
4.12M
8.56%
--
--
Sep 30, 2025
Deep Track Capital LP
3.95M
8.21%
--
--
Sep 30, 2025
Alphabet, Inc.
2.41M
5.01%
--
--
Sep 30, 2025
Andreessen Horowitz
1.70M
3.54%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.33M
2.77%
+915.34K
+218.14%
Sep 30, 2025
Matrix Capital Management Company, LP
1.65M
3.44%
-832.50K
-33.49%
Sep 30, 2025
VR Adviser, LLC
1.23M
2.56%
+1.23M
--
Sep 30, 2025
Logos Global Management LP
1.23M
2.55%
+615.39K
+100.57%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
0.53%
ALPS Medical Breakthroughs ETF
0.39%
iShares Micro-Cap ETF
0.12%
iShares Russell 2000 Value ETF
0.04%
ProShares UltraPro Russell2000
0.03%
ProShares Hedge Replication ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
Schwab U.S. Small-Cap ETF
0.02%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.53%
ALPS Medical Breakthroughs ETF
Proporción0.39%
iShares Micro-Cap ETF
Proporción0.12%
iShares Russell 2000 Value ETF
Proporción0.04%
ProShares UltraPro Russell2000
Proporción0.03%
ProShares Hedge Replication ETF
Proporción0.03%
iShares Russell 2000 ETF
Proporción0.02%
Proshares Ultra Russell 2000
Proporción0.02%
Schwab U.S. Small-Cap ETF
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
